Evidence to practice: Botulinum toxin in the treatment of spasticity post stroke

Topics in Stroke Rehabilitation

Volumn 19, Issue 2, 2012, Pages 115-121

  Teasell, Robert ^a,b,c   Foley, Norine ^b   Pereira, Shelialah ^b   Sequeira, Keith ^a,c   Miller, Thomas ^a,c  

^a ST JOSEPH S HEALTH CENTRE   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c WESTERN UNIVERSITY   (Canada)

Author keywords

botulinum toxin type A; spasticity; stroke

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ARM; EVIDENCE BASED MEDICINE; HEMIPLEGIA; HUMAN; LEG; MUSCLE DENERVATION; QUALITY OF LIFE; REVIEW; SHOULDER; SHOULDER PAIN; SPASTICITY; STROKE;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; EVIDENCE-BASED MEDICINE; HUMANS; MUSCLE SPASTICITY; STROKE;

EID: 84860117067     PISSN: 10749357     EISSN: 19455119     Source Type: Journal    
DOI: 10.1310/tsr1902-115     Document Type: Review

References (52)

1. Lance JW. Symposium synopsis: In: Feldman RG, Young RR, Koella WP, eds. Spasticity: Disordered Motor Control. Chicago: Year Book Medical Publishers; 1980.
2. Thilmann AF. Spasticity: history, definition, and usage of the term. In: Thilmann AF, Burke DJ, Rymer WZ, eds. Spasticity Mechanisms and Management. New York: Springer-Verlag; 1993.
3. Watkins C, Leathley M, Gregson J, Moore A, Smith T, Sharma A. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16(5):515.
4. Rosales R, Chua-Yap A. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm. 2008;115(4):617-623.
5. Simpson D, Alexander D, O'Brien C, et al. Botulinum toxin type A in the treatment of upper extremity spasticity. Neurology. 1996;46(5):1306.
6. Gallichio JE. Pharmacologic management of spasticity following stroke. Phys Ther. 2004;84(10):973.
7. Suputtitada A, Suwanwela N. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil. 2005;27(4):176-184.
8. Bell KR, Williams F. Use of botulinum toxin type A and type B for spasticity in upper and lower limbs. Phys Med Rehabil Clin N Am. 2003;14(4):821-835.
9. Centre for Evidence-Based Physiotherapy. PEDro scale. http://www.pedro.org.au/english/downloads/pedro-scale/. Updated August 1, 2011.
10. Teasell R, Salter K, Foley N. Introduction and methods. In:Stroke Rehabilitation Evidence-Based Review. 13th ed. http://ebrsr.com/uploads/Module- 1-introduction-001.pdf.
11. Gracies JM, Singer BJ, Dunne JW. The role of botulinum toxin injections in the management of muscle overactivity of the lower limb. Disabil Rehabil. 2007;29(23):1789-1805.
12. Burbaud P, Wiart L, Dubos J, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry. 1996;61(3):265.
13. Pittock S, Moore A, Hardiman O, et al. A doubleblind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2000;15(4): 289-300.
14. Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinum toxin type A in the treatment of spastic foot after stroke. A randomized, double-blind trial. Am J Phys Med Rehabil. 1998;77(6):510.
15. Childers MK, Stacy M, Cooke DL, Stonnington HH. Comparison of two injection techniques using botulinum toxin in spastic hemiplegia. Am J Phys Med Rehabil. 1996;75(6):462.
16. Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomised, double-blind, doseranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci. 2005;26(1):26-31.
17. On AY, Kirazli Y, Kismali B, Aksit R. Mechanisms of action of phenol block and botulinum toxin Type A in relieving spasticity: electrophysiologic investigation and follow-up. Am J Phys Med Rehabil. 1999;78(4):344.
18. Reiter F, Danni M, Lagalla G, Ceravolo G, Provinciali L. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil. 1998;79(5): 532-535.
19. Foley N, Murie-Fernandez M, Speechley M, Salter K, Sequeira K, Teasell R. Does the treatment of spastic equinovarus deformity following stroke with botulinum toxin increase gait velocity? A systematic review and meta-analysis. Eur J Neurol. 2010;17(12):1419-1427.
20. Bayram S, Sivrioglu K, Karli N, Ozcan O. Lowdose botulinum toxin with short-term electrical stimulation in poststroke spastic drop foot: a preliminary study. Am J Phys Med Rehabil. 2006;85(1):75.
21. Johnson CA, Wood DE, Swain ID, Tromans AM, Strike P, Burridge JH. A pilot study to investigate the combined use of botulinum neurotoxin type A and functional electrical stimulation, with physiotherapy, in the treatment of spastic dropped foot in subacute stroke. Artif Organs. 2002;26(3):263-266.
22. Baricich A, Carda S, Bertoni M, Maderna L, Cisari C. A single-blinded, randomized pilot study of botulinum toxin type A combined with nonpharmacological treatment for spastic foot. J Rehabil Med. 2008;40(10):870-872.
23. Van Kuijk A, Geurts A, Bevaart B, Van Limbeek J. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature. J Rehabil Med. 2002;34(2):51-61.
24. Francis H, Wade D, Turner-Stokes L, Kingswell R, Dott C, Coxon E. Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg Psychiatry. 2004;75(11):1547.
25. Bakheit A, Thilmann A, Ward A, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000;31(10):2402.
26. Bakheit A, Pittock S, Moore A, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 2001;8(6):559-565.
27. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in poststroke upper limb spasticity. Curr Med Res Opin. 2010;26(8):1983-1992.
28. Brashear A, McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2004;85(5):705-709.
29. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347(6):395-400.
30. McCrory P, Turner-Stokes L, Baguley IJ, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med. 2009;41(7):536-544.
31. Kanovsky P, Slawek J, Denes Z. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009;32(5):259.
32. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebocontrolled study. J Neurol Neurosurg Psychiatry. 2009;80(4):380.
33. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000;69(2):217.
34. Bhakta BB, O'Connor RJ, Cozens AJ. Associated reactions after stroke: a randomized controlled trial of the effect of botulinum toxin type A. J Rehabil Med. 2008;40(1):36-41.
35. Smith S, Ellis E, White S, Moore A. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil. 2000;14(1):5.
36. Francisco GE, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil. 2002;81(5):355-363.
37. Childers MK, Brashear A, Jozefczyk P, et al. Dosedependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004; 85:1063-1069.
38. Meythaler JM, Vogtle L, Brunner RC. A preliminary assessment of the benefits of the addition of botulinum toxin a to a conventional therapy program on the function of people with longstanding stroke. Arch Phys Med Rehabil. 2009;90(9):1453-1461.
39. Sun SF, Hsu CW, Sun HP, Hwang CW, Yang CL, Wang JL. Combined botulinum toxin type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study. Neurorehabil Neural Repair. 2010;24:34-41.
40. Jahangir AW, Tan HJ, Norlinah MI, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. Med J Malaysia. 2007;62:319-322.
41. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb fl exor spasticity after stroke: a randomized, double-blind, placebocontrolled trial. Clin Rehabil. 1998;12(5):381.
42. Turner-Stokes L, Baguley IJ, De Graff S, et al. Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double-blind placebocontrolled randomized clinical trial. J Rehabil Med. 2010;42:81-89.
43. Sackley C, Brittle N, Patel S, et al. The prevalence of joint contractures, pressure sores, painful shoulder, other pain, falls, and depression in the year after a severely disabling stroke. Stroke. 2008;39(12):3329.
44. Kaplan PE, Meridith J, Taft G, Betts HB. Stroke and brachial plexus injury: a difficult problem. Arch Phys Med Rehabil. 1977;58(9):415-418.
45. Marco E, Duarte E, Vila J, et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A doubleblind randomized clinical trial. J Rehabil Med. 2007;39(6):440-447.
46. Yelnik AP, Colle FM, Bonan IV, Vicaut E. Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A. J Neurol Neurosurg Psychiatry. 2007;78(8):845.
47. Lim JY, Koh JH, Paik NJ. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke. 2008;39(1):126.
48. Kong KH, Neo JJ, Chua KSG. A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. Clin Rehabil. 2007;21(1):28.
49. De Boer K, Arwert H, De Groot J, Meskers C, Mishre A, Arendzen J. Shoulder pain and external rotation in spastic hemiplegia do not improve by injection of botulinum toxin A into the subscapular muscle. J Neurol Neurosurg Psychiatry. 2008;79(5):581.
50. Lindsay P, Gubitz G, Bayley M, et al. Canadian Best Practice Recommendations for Stroke Care (updated 2010). Ottawa, Ontario, Canada: Canadian Stroke Strategy Best Practices and Standards Writing Group; 2010.
51. Shaw LC, Price CIM, van Wijck FMJ, et al. Botulinum toxin for upper limb after stroke (BoTULS) Trial: effect on impairment, activity limitation and pain. Stroke. 2011;42:1371-1379.
52. Wissel J, Ward AB, Erztgaard P, et al. European Consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41: 13-25.